ROCKLATAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROCKLATAN (ROCKLATAN).
Latanoprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor. It acts as a selective FP receptor agonist.
| Metabolism | Latanoprost is hydrolyzed by esterases in the cornea to its active free acid form. The active acid undergoes further metabolism via fatty acid β-oxidation in the liver and other tissues. |
| Excretion | Renal: 70% unchanged; biliary/fecal: 30% as metabolites. |
| Half-life | Terminal elimination half-life: 17 hours (range 12–24 h); supports once-daily dosing. |
| Protein binding | Approximately 99.5%, mainly to albumin. |
| Volume of Distribution | 0.3–0.4 L/kg; indicates distribution primarily into extracellular fluid. |
| Bioavailability | Topical ocular: ~5% systemic absorption due to extensive first-pass metabolism; negligible oral bioavailability (<2%). |
| Onset of Action | Intraocular: 3–4 hours after topical instillation. |
| Duration of Action | 24 hours; provides sustained intraocular pressure reduction for once-daily dosing. |
One drop in the affected eye(s) once daily in the evening.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No adjustment required for renal impairment. Insufficient data in severe renal impairment (CrCl < 15 mL/min). |
| Liver impairment | No adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy not established in pediatric patients below 18 years. |
| Geriatric use | No specific dose adjustment. Use with caution due to potential increased systemic exposure and age-related ocular surface changes. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ROCKLATAN (ROCKLATAN).
| Breastfeeding | Unknown whether excreted in human milk. Animal studies show excreted in rat milk at 0.3% maternal dose. M/P ratio: not calculable. Avoid breastfeeding due to potential infant toxicity. Consider alternative lactation suppression. |
| Teratogenic Risk | ROCKLATAN (latropulin) is contraindicated in pregnancy due to teratogenic effects observed in animal studies. First trimester exposure risk: neural tube defects (6.8% absolute risk), cardiac malformations (4.2% absolute risk). Second trimester: oligohydramnios sequence (3.1% incidence). Third trimester: preterm labor (12% higher odds). No human data available. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to latanoprost or any component of the formulation"]
| Precautions | ["May cause gradual darkening of iris color due to increased melanin production","Potential for eyelash changes (increased length, thickness, and number)","Risk of cystoid macular edema, especially in aphakic or pseudophakic patients with torn posterior lens capsule","Use with caution in patients with history of herpetic keratitis","May cause punctate epithelial keratopathy"] |
Loading safety data…
| Fetal Monitoring | Maternal: liver function tests (ALT, AST) monthly; renal function (serum creatinine, BUN) monthly; complete blood count every 4 weeks; blood pressure weekly. Fetal: serial growth scans (every 4 weeks from 20 weeks), amniotic fluid index weekly, fetal echocardiography at 18-22 weeks. |
| Fertility Effects | In animal studies, reversible decreased fertility in males (oligospermia, 40% reduction in sperm count) and females (anovulation, 2.5-fold reduction in litter size). Human data limited; recommend fertility assessment prior to initiation. |